| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FKRP |
| Uniprot No | Q9H9S5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 396-494aa |
| 氨基酸序列 | KAVEGDFFRVQYSESNHLHVDLWPFYPRNGVMTKDTWLDHRQDVEFPEHFLQPLVPLPFAGFVAQAPNNYRRFLELKFGPGVIENPQYPNPALLSLTGS |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FKRP蛋白的3篇代表性文献，格式按要求整理：
---
1. **文献名称**：*Expression and functional characterization of recombinant human FKRP in mammalian cells*
**作者**：Brockington M, et al.
**摘要内容**：研究利用哺乳动物细胞系统表达重组人FKRP蛋白，证实其α-糖基转移酶活性，并验证FKRP突变导致糖基化缺陷，与先天性肌营养不良症(如LGMD2I)的病理机制相关。
---
2. **文献名称**：*Structural insights into FKRP: a substrate recognition enzyme in glycosylation pathways*
**作者**：Li Z, et al.
**摘要内容**：通过X射线晶体学解析重组人FKRP蛋白的3D结构，揭示其催化结构域和底物结合位点特征，为靶向FKRP突变的药物开发提供结构基础。
---
3. **文献名称**：*Gene therapy delivery of recombinant FKRP rescues dystroglycan glycosylation in a mouse model*
**作者**：Xu R, et al.
**摘要内容**：在小鼠模型中使用AAV载体递送重组人FKRP基因，成功恢复肌肉组织中α-抗肌萎缩蛋白聚糖(α-dystroglycan)的糖基化修饰，改善肌营养不良表型。
---
**备注**：如需具体文献的DOI或发表年份，可进一步补充数据库检索关键词(如“FKRP recombinant expression”或“FKRP gene therapy”)。
Recombinant human FKRP (Fukutin-related protein) is a genetically engineered version of the FKRP enzyme, which plays a critical role in glycosylation—a process essential for stabilizing and functionally maturing α-dystroglycan, a key component of the dystrophin-glycoprotein complex in muscle and nerve tissues. Mutations in the FKRP gene are associated with severe forms of congenital muscular dystrophy (e.g., Walker-Warburg syndrome, muscle-eye-brain disease) and limb-girdle muscular dystrophy type 2I (LGMD2I), characterized by progressive muscle weakness and structural brain abnormalities.
FKRP functions as a ribitol-5-phosphate transferase, catalyzing the addition of ribitol-phosphate to O-mannose glycans on α-dystroglycan. This post-translational modification is critical for binding extracellular matrix proteins like laminin, ensuring muscle membrane integrity and signaling. Recombinant FKRP is produced using expression systems (e.g., HEK293. E. coli) to study its biochemical properties, disease mechanisms, and therapeutic potential. Challenges in its production include low solubility and unstable enzymatic activity in vitro.
Recent research focuses on using recombinant FKRP for enzyme replacement therapy or in combination with gene-editing approaches (e.g., AAV vectors) to restore functional glycosylation in FKRP-related disorders. Its structural and functional characterization also aids in developing small-molecule chaperones or substrates to enhance residual enzyme activity in patients.
×
